Medicalcv Inc

Medicalcv — Investor Presentation (March 2007)

33 slides from Medicalcv's investor presentation, Mar 16, 2007

  1. Slide 1: Investor Presentation March 16, 2007

    Investor Presentation March 16, 2007 Presented by: Marc Flores, CEO Eapen Chacko, CFO Adam Berman, VP of R&D 0

  2. Slide 2: Forward-Looking Statement Disclaimer

    This presentation contains certain forward-looking statements of expected future developments, as defined in the Private Securities Litigation Reform Act of 1995. The forward-looking statements in this presentation refer to the Company’s expectations regarding the development, regulatory clearance a

  3. Slide 3: Introduction

    Company: MedicalCV, Inc. Market: OTC Bulletin Board Symbol: “MCVI” Recent Stock Price(1): $2.10 Market Capitalization(1): $20.6 million – 9.8 million Common Shares $25.2 million – 12.0 million Fully-Diluted Shares Introduction (1) Based on the closing bid price on March 8, 2007. 2

  4. Slide 4: Company Profile & Recent Developments

    Incorporated: In March 1992, as a Minnesota Corporation Redirected: In August 2004, newly repopulated management redirects company to new market Purpose: Fulfill unmet cardiovascular surgery needs Long Term Objective: Develop stand-alone, closed chest, beating heart treatment for Atrial Fibrillation

  5. Slide 5: Company Vision

    Company Vision Dedicated to Developing Stand-Alone, Closed Chest, Beating Heart Treatment for Atrial Fibrillation Committed to Becoming Market Leader in Surgical Treatment of Atrial Fibrillation 4

  6. Slide 6: Business Strategy

    Market ATRILAZE™ Surgical Ablation Wands* Concomitant Open Heart Procedures (CABG & VALVE) Closed Chest, Robotic/Endoscopic Beating Heart Procedures Ideal for Multiple Lesions Sets & Ganglionated Plexi Introduce SOLAR™ Surgical Ablation System** Expect it to be used as both a stand-alone product and

  7. Slide 7: Investment Highlights

    Investment Highlights Experienced management team with strong track record of execution and demonstrated medical device success Treatment of Atrial Fibrillation is a large and growing market opportunity* Uniquely positioned to offer stand-alone soft tissue ablation procedure following FDA clearance

  8. Slide 8: Market Overview

    Market Overview Atrial Fibrillation (AF) is an irregular heartbeat in which abnormal electrical impulses cause the upper chambers of the heart (atria) to fibrillate, or quiver, at rapid rates of 400 to 600 times per minute, resulting in an inefficient cardiac cycle, characterized by inadequate ventr

  9. Slide 9: AF Treatment Options

    AF Treatment Options Drugs (Palliative) Success rate 50% (1-yr), 40% (2-yrs) Catheter-Based* (Palliative/Curative) Success rate of 40% to 70% Surgical* (Curative) Open chest Maze Procedure Disassemble/Reassemble (Cut & Sew) Success rate of >90% MedicalCV’s stand-alone soft tissue ablation system** S

  10. Slide 10: Lone AF Opportunity

    Lone AF Opportunity AF Patients* 5,000,000 50% Asymptomatic** 2,500,000 50% Drug Responsive** 1,250,000 Stand-Alone Market Potential 1,250,000 *Miyasaki Y, et al. Secular Trends in Incidence of Atrial Fibrillation in Olmstead County, Minnesota, 1980 to 2000, and Implications on the Projections for F

  11. Slide 11: Reimbursement: Hospital & Physician

    Reimbursement: Hospital & Physician ’07 Hospital Revenues for Concomitant Cardiac Ablation (CABG) Payment (DRG 547-550): ~$25,795 3-5 Day Stay Net Profit per Procedure: ~$5-10K ’07 Hospital Revenues for Stand Alone Cardiac Ablation Payment (DRG 108): ~$30,500 1-3 Day Stay Net Profit per Procedure: ~

  12. Slide 12: MedicalCV's Laser Platform

    MedicalCV’s Laser Platform 1064nm Wavelength Focused, High Energy Transmission Minimal Energy Spread/Dispersion Optimized for Beating Heart Application on Atrial Tissue Sub-Millimeter Fiber Optic Narrow, Full Thickness Tissue Lesion (<3mm) Miniaturization of Delivery System Flexibility for Single-Si

  13. Slide 13: ATRILAZE: Generation 510(k) Cleared for Cardiac Tissue Ablation

    ATRILAZE™: Generation 1 510(k) Cleared for Cardiac Tissue Ablation 12

  14. Slide 14: ATRILAZE: Generation 510(k) Cleared for Cardiac Tissue Ablation

    ATRILAZE™ : Generation 2 510(k) Cleared for Cardiac Tissue Ablation 13

  15. Slide 15: ATRILAZE Surgical Ablation System

    ATRILAZE™ Surgical Ablation System 510(k) Cleared for Cardiac Tissue Ablation 14 [video showing application of ATRILAZE System]

  16. Slide 16: ATRILAZE Clinical Experience to Date

    ATRILAZE™ Clinical Experience to Date 40 Concomitant Procedures to Date Northwestern University (Chicago, IL) Baylor Medical Center (Dallas, TX) Christus Santa Rosa (San Antonio, TX) Banner Heart Hospital (Mesa, AZ) Shea Scottsdale (Scottsdale, AZ) Performed on Arrested Heart Thoracotomy Mini-Thorac

  17. Slide 17: ATRILAZE Clinical Results to Date

    ATRILAZE™ Clinical Results to Date 16 Patient Study (Baylor Medical Center) Concomitant Procedures CABG, MVR, MVR/CABG, AVR, & ASD Ablation Procedure Time: 2-15 minutes Chronic AF: 6 Patients Paroxysmal AF: 10 Patients 30-Day Follow-Up 13/14 Free of AF 60-Day Follow-Up 9/10 Free of AF 6-Month Follow

  18. Slide 18: SOLAR Surgical Ablation System

    SOLAR™ Surgical Ablation System 510(k) Pending for Soft Tissue Ablation 17

  19. Slide 19: Scientific Advisory Board

    Patrick M. McCarthy, MD (C) Northwestern University Lishan Aklog, MD Mount Sinai Medical Center Michael P. Caskey, MD Scottsdale, AZ Marc Gerdisch, MD Chicago, IL Baron L. Hamman, MD Baylor University Ralph Lazzara, MD University of Oklahoma Robert R. Lazzara, MD Tampa, FL Yousuf Mahomed, MD Indiana

  20. Slide 20: SOLAR Surgical Ablation System

    Laser Controller Orbital Track 19 SOLAR™ Surgical Ablation System

  21. Slide 21: SOLAR System Pre-Clinical Video

    SOLAR™ System Pre-Clinical Video Click on Image for Printable Copy 20

  22. Slide 22: SOLAR System Animation

    SOLAR™ System Animation 510(k) Pending for Soft Tissue Ablation Only; Minimally Invasive Cardiac Tissue Indication Requires Additional FDA Filing(s) 21

  23. Slide 23: MedicalCV Intellectual Property Portfolio

    MedicalCV Intellectual Property Portfolio 22 3 Issued US Patents #7,137,977: Atraumatic Laser Tip for AF Treatment #7,163,534: Laser-Based Maze Procedure for AF #7,169,142: Malleable Energy Wand for Maze Procedure 1 US Notice of Allowance Apparatus AND Method of Laser Treatment 13 Additional US Pate

  24. Slide 24: SOLAR System Launch Strategy

    SOLAR™ System Launch Strategy 6-Month Controlled Launch Focus on 4 High Volume Markets Focus on 6 Large Volume Hospitals “Go Deep” vs. “Go Wide” penetration strategy Estimated Pricing Disposable Component: $5-7.5K (Years 1 - 5) Capital Components: Capital Recovery Charge (Year 1 Accounts) $95K (Year

  25. Slide 25: Competition

    Competition Technology Weaknesses Companies Strengths Radiofrequency Established Technology (RF Energy) Established Customer Base Good Concomitant Results Easy & Fast to Use No True Minimally Invasive System Existing System Requires 3-5 Day Length of Stay & Bilateral Thoracotomy Microwave Can be use

  26. Slide 26: Financial Highlights

    Financial Highlights 25:

  27. Slide 27: Balance Sheet

    Balance Sheet Cash burn rate of $1.0M per month External development of capital equipment Internal development of disposable $2.2M (net) from Potomac PIPE financing in October 2006 Cash on hand to finance operations through April 30, 2007 $11.6M $4.9M Total Liabilities & Equity $7.7M $1.5M Equity $2

  28. Slide 28: Fully Diluted Capitalization (1/31/07)

    Fully Diluted Capitalization (1/31/07) 12,039,145 1,288,638 913,283 9,837,224 # Outstanding $7.49 Warrants $8.78 Options Common Stock Avg. Exercise Price Market capitalization of $20.7M as of March 8, 2007 ($2.10 per share) No preferred stock outstanding at January 31, 2007 750,687 warrants have wei

  29. Slide 29: Income Statement

    Income Statement 9 months ended 1/31/07 $1.5M of non-cash SFAS 123R expense $1.6M external development of controller $0.5M external development of laser $0.6M materials and temp labor to build prototypes of disposable 9 months ended 1/31/06 $16.5M of non-cash change in FMV of putable warrants (from

  30. Slide 30: Appendix

    Appendix 29

  31. Slide 31: Epicardial Ablation (Endocardial View)

    Epicardial Ablation (Endocardial View) 30

  32. Slide 32: Histology: Atrial Appendage

    Histology: Atrial Appendage 31

  33. Slide 33: ATRILAZE: G1 Beating Heart 510(k) Cleared for Cardiac Tissue Ablation

    ATRILAZE™: G1 Beating Heart 510(k) Cleared for Cardiac Tissue Ablation 32

Medicalcv — Investor Presentation (March 2007) on 6ix